TrialPsychopharmacology bulletin2021

A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended-Release) in Adolescents with ADHD.

Azmi Nasser et al.PubMed ↗Full text ↗

No numbers read from the abstract.